WO2004082721A1 - Complexes of gd +3 gadolinium ions with derivatives of n-2- (2- (phenylamino) -2- oxoethyl) -n- (carboxymethyl) - glycine and method for obtaining these complexes - Google Patents

Complexes of gd +3 gadolinium ions with derivatives of n-2- (2- (phenylamino) -2- oxoethyl) -n- (carboxymethyl) - glycine and method for obtaining these complexes Download PDF

Info

Publication number
WO2004082721A1
WO2004082721A1 PCT/PL2004/000017 PL2004000017W WO2004082721A1 WO 2004082721 A1 WO2004082721 A1 WO 2004082721A1 PL 2004000017 W PL2004000017 W PL 2004000017W WO 2004082721 A1 WO2004082721 A1 WO 2004082721A1
Authority
WO
WIPO (PCT)
Prior art keywords
atom
group
amine
derivatives
oxoethyl
Prior art date
Application number
PCT/PL2004/000017
Other languages
French (fr)
Inventor
Elzbieta Olasik
Boleslaw Karwowski
Malgorzata Witczak
Michal Studniarek
Original Assignee
Uniwersystet Medyczny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersystet Medyczny filed Critical Uniwersystet Medyczny
Publication of WO2004082721A1 publication Critical patent/WO2004082721A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • A61K49/101Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/103Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA

Definitions

  • the subject of the invention are new complexes of Gd +3 gadolinium ions with derivatives of 2,2'-(2- (R ⁇ ,R 2 ,R 3 ,R 4 ,R 5 -phenyl)amine)-2- oxyethyl))diacetic acid of the formula I, in which R l 5 R 2 ,R 3 ,R 4 and R 5 are the same or different and they stand for either an atom of hydrogen or an atom of halogen or an aliphatic group or an aromatic group or a nitro group or a phosphonic group or a phosphate group or a heterocyclic system containing an atom of oxygen of an atom of nitrogen or an atom of sulphur of any configuration and a method for these compounds obtaining.
  • the compounds being the subject of the invention are new and they have not been described in any chemical literature. Initial research indicates a possibility to apply these new compounds as contrasting for non-invasive diagnostic technique in medical imaging, for instance magnetic nuclear resonance for internal organs particularly liver. There are known radioactive complexes of technetium 99 " 1 Tc and iodine I for liver diagnostics by scanning techniques and CT
  • liver diagnostics for instance in biliary canalicula occlusion.
  • Tests performed with their application have low resolving power in comparison to the results achieved by the MRJ technique.
  • the mole ratio of the reagents is 1 : 2.
  • Gadolinium complex lithium salt obtained in the above mentioned way is transformed into a derivative of sodium salt in reaction with sodium hydroxide.
  • the medium of the reaction is aliphatic alcohol or aliphatic amine or aromatic amine or dimethylsulfoxide (DMSO) or dimethylformamide.
  • the reaction is carried out at the room temperature and the ratio of the reagents is 1 : 1.
  • the obtained new gadolinium complex is purified by a known method.
  • Ligands for new complexes of derivatives of 2,2'-(2-(R 1 R 2 ,R 3 ,R ,R 5 - phenyl)amine)-2-oxoethyl))diacetic acid, being an initial product for synthesis with hexahydrous gadolinium oxide according to the invention is obtained in reaction between appropriately substituted derivatives of aniline and mixed anhydride of nitrilotriacetic acid and acetic acid (Nunn A.D., Loberg M.D., US Patent N° 4,418,208).
  • the process yield was 85%.

Abstract

Method for obtaining new complexes of Gd+3 gadolinium ions with derivatives of 2,2'-(2­(R1, R2, R3, R4, R5-phenyl)amine)-2-oxoethyl))diacetic acid of the formula (I), in which R1, R2, R3, R4 and R5 are the same or different and stand for an atom of hydrogen or an atom of halogen or an aliphatic group or an aromatic group or a nitro group or a phosphonic group or a phosphate group or a heterocyclic system including an atom of oxygen or an atom of nitrogen or an atom of sulphur, characterized in that hexahydrous gadolinium chloride is exposed to reaction with lithium salt of derivatives of 2,2'-(2-(R1, R2, R3, R4, R5-phenyl)amine)-2-oxoethyl)) diacetic acid in the medium of aliphatic alcohol, aliphatic amine, aromatic amine, dimethylsulfoxide (DMSO), dimethylformemide (DMF) at the temperature 60 °C, providing that the mole ratio of the reagents is 1:2, and next the obtained lithium salt of gadolinium complex is transformed into sodium salt which is purified by a known method. The new compounds can be applied as contrast media for non-invasive diagnostic technique, in medical imaging as for instance nuclear resonance for interior organs particularly liver.

Description

COMPLEXES OF GD +3 GADOLINIUM IONS WITH DERIVATIVES OF N-2- (2- (PHENYLAMINO) -2-OXOETHYL) -N- ( CARBOXYMETHYL) -GLYCINE AND METHOD FOR
OBTAINING THESE COMPLEXES
New Complexes of Gd+3 Gadolinium Ions with Derivatives of 2,2'- (2-(Rι ,R2,R3,R4,R5-phenyl) amine)-2-oxoethyl))diacetic Acid and
Method for Obtaining New Complexes of Gd Gadolinium Ions with Derivatives of 2,2'-(2-(Rι ,R2,R3,R4,R5-phenyl)amine)-2- oxyethyl))diacetic Acid.
The subject of the invention are new complexes of Gd+3 gadolinium ions with derivatives of 2,2'-(2- (Rι ,R2,R3,R4,R5-phenyl)amine)-2- oxyethyl))diacetic acid of the formula I, in which Rl 5R2,R3,R4 and R5 are the same or different and they stand for either an atom of hydrogen or an atom of halogen or an aliphatic group or an aromatic group or a nitro group or a phosphonic group or a phosphate group or a heterocyclic system containing an atom of oxygen of an atom of nitrogen or an atom of sulphur of any configuration and a method for these compounds obtaining.
The compounds being the subject of the invention are new and they have not been described in any chemical literature. Initial research indicates a possibility to apply these new compounds as contrasting for non-invasive diagnostic technique in medical imaging, for instance magnetic nuclear resonance for internal organs particularly liver. There are known radioactive complexes of technetium99"1 Tc and iodine I for liver diagnostics by scanning techniques and CT
(computer tomography), being derivatives of the nitrilotriacetic acid system including various substituents. Their main application is in liver diagnostics, for instance in biliary canalicula occlusion.
Tests performed with their application have low resolving power in comparison to the results achieved by the MRJ technique.
Technetium complexes do not allow diagnostics of small lesions.
The known contrast media used in CT for liver diagnostics require application of high doses, which is connected with their toxicity increase.
According to the invention new complexes of gadolinium GD+ are obtained in reaction of hexahydrous gadolinium chloride
[GdCl3(H2O)6] with lithium salt of derivatives of 2,2' -(2-
(Rι .R2,R3,R4,R5-phenyl)amine)-2-oxyethyl))diacetic acid in the medium of aliphatic alcohol, aliphatic amine, aromatic amine, dimethylsulfoxide (DMSO), dimethylformamide (DMF) at the temperature of 60°C.
The mole ratio of the reagents is 1 : 2.
Gadolinium complex lithium salt obtained in the above mentioned way is transformed into a derivative of sodium salt in reaction with sodium hydroxide.
The medium of the reaction is aliphatic alcohol or aliphatic amine or aromatic amine or dimethylsulfoxide (DMSO) or dimethylformamide.
The reaction is carried out at the room temperature and the ratio of the reagents is 1 : 1.
The obtained new gadolinium complex is purified by a known method. Ligands for new complexes of derivatives of 2,2'-(2-(R1R2,R3,R ,R5- phenyl)amine)-2-oxoethyl))diacetic acid, being an initial product for synthesis with hexahydrous gadolinium oxide according to the invention is obtained in reaction between appropriately substituted derivatives of aniline and mixed anhydride of nitrilotriacetic acid and acetic acid (Nunn A.D., Loberg M.D., US Patent N° 4,418,208).
Identity of the new gadolinium complexes obtained according to the invention and structure of obtained combinations have been confirmed by elementary analysis and spectrally (IR, FAB MS,
MALDI TOF).
Biological tests performed with animals showed that new compounds were preparations of selective affinity for liver structures and they are of low toxicity.
The idea of the invention is explained more closely on the below example.
Example:
Obtaining sodium salt of gadolinium complex with 2,2'-(2-
(phenyl amine -2-oxoethyl )diacetic acid
1 weight part of lithium salt of 2,2'-(2-(phenyl)amine)-2- oxoethyl))diacetic acid was dissolved in 10.6 weight parts of methanol and mixed with 0.67 weight part of GdCl36H O dissolved in 4.26 weight parts of methanol; the obtained solutions being mixed for 24 hours at the temperature of 60°C. Next there was added 0.7 weight part of NaOH solved in 6.4 weight parts of methanol. After
30 minutes the solvent was evaporated and the residue was crystallised from the methanol/acetonitrile system.
The process yield was 85%.
Rf (MeOH) - 0.56 t.t.->300°C IR (cm"1): 3403.9 (H2O), 3078.7 (Ph), 1630.6; 1598.5 (C=0)
MS (-FAB): (m/z) 683, 684.2, 685, 686.2, 688.1 (M1); 706, 708.1
(M_1+Na)
MALDI TOF: (m/z) 685, 686, 687, 689 (M"1)
Elemental analysis:C24H24Gd N4O10Na 6(H2O) 6(CO2)
Calculated: C(33.34%) ,H(3.36%) Gd(14.55%) N(5.18%) Na(2.13%)
0(41.45%)
Obtained: C(33.0%) H(3.32%) N(5.43%)

Claims

Claims
1. New complexes of Gd+3 gadolinium ions with derivatives of 2,2'-(2-(Rl 5R2,R3,R4,R5-phenyl)amine)-2-oxoethyl))acetic acid of the formula I, in which Ri, R2, R3, R4 and R5 are the same or different and they stand for an atom of hydrogen or an atom of halogen or an aliphatic group or an aromatic group or a nitro group or a phosphonic group or a phosphate group or a heterocyclic system including an atom of oxygen, an atom of nitrogen or an atom of sulphur.
2. Method for obtaining new complexes of Gd gadolinium ions with derivatives of 2,2'-(2-(Rl 5R2,R3,R4,R5-phenyl)amine)-2- oxoethyl))diacetic acid of the formula I, in which Ri, R2, R3, R4 and R5 are the same or different and they stand for an atom hydrogen or an atom of halogen or an aliphatic group or an aromatic group or a nitro group or a phosphonic group or a phosphate group or a heterocyclic system including an atom of oxygen or an atom of nitrogen or an atom of sulphur, characterised in that hexahydrous gadolinium chloride is exposed to a reaction with lithium salt of derivatives of 2,2' -(2- (Rι ,R2,R ,R4,R5-phenyl)amine)-2-oxoethyl))diacetic acid in the medium of aliphatic alcohol, aliphatic amine, aromatic amine, dimethylsulfoxide (DMSO), dimethylformamide (DMF) at the temperature of 60°C, providing that the mole ratio of the reagents is 1 :2, next lithium salt of gadolinium complex is transformed into sodium salt which is purified by a known method.
PCT/PL2004/000017 2003-03-20 2004-03-12 Complexes of gd +3 gadolinium ions with derivatives of n-2- (2- (phenylamino) -2- oxoethyl) -n- (carboxymethyl) - glycine and method for obtaining these complexes WO2004082721A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL35924903A PL359249A1 (en) 2003-03-20 2003-03-20 New gadolinium gd+3 ion complexes with derivatives of the 2,2'-(2-(r1, r2, r3, r4, r5-phenyl) amino) -2-oxoethyl)) diacetic acid and method for obtaining new gadolinium gd+3 ion complexes with derivatives of the 2,2'-(2-(r1, r2, r3, r4, r5-phenyl) amino) -2-oxoethyl)) diacetic acid
PLP-359249 2003-03-20

Publications (1)

Publication Number Publication Date
WO2004082721A1 true WO2004082721A1 (en) 2004-09-30

Family

ID=33029126

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/PL2004/000017 WO2004082721A1 (en) 2003-03-20 2004-03-12 Complexes of gd +3 gadolinium ions with derivatives of n-2- (2- (phenylamino) -2- oxoethyl) -n- (carboxymethyl) - glycine and method for obtaining these complexes

Country Status (2)

Country Link
PL (1) PL359249A1 (en)
WO (1) WO2004082721A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0165728A1 (en) * 1984-05-30 1985-12-27 Nycomed As NMR contrast agents

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0165728A1 (en) * 1984-05-30 1985-12-27 Nycomed As NMR contrast agents

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; NAJAFI, A. ET AL: "Gadolinium -labeled pharmaceuticals as potential MRI contrast agents for liver and biliary tract", XP002288484, retrieved from STN Database accession no. 1988:2748 *
JOURNAL OF LABELLED COMPOUNDS AND RADIOPHARMACEUTICALS , 24(9), 1131-41 CODEN: JLCRD4; ISSN: 0362-4803, 1987 *

Also Published As

Publication number Publication date
PL359249A1 (en) 2004-10-04

Similar Documents

Publication Publication Date Title
EP1184377B1 (en) Hepatobiliary magnetic resonance contrast agents
JP2509247B2 (en) Novel complex compound, production method thereof and diagnostic agent containing this compound
DE3625417C2 (en) Tetraazacyclododecane derivatives
EP3386954B1 (en) Dimeric contrast agents
RU2743167C2 (en) Contrast agents
RU2232763C2 (en) Metal complexes with bicyclic polyamino acids, method for their preparing and their application in medicine for image preparing
US4698431A (en) Hydroxypyridonate chelating agents
EP0352218B1 (en) Macrocyclic polyaza compounds containing rings with 5 or 6 members, methods for their preparation and pharmaceutical compositions containing same
EP3442949B1 (en) Contrast agents
NO180582B (en) Diethylenetriamine acetic acid monoamides (DTPA monoamides), complexes and complex salts thereof, and use of the compounds for the preparation of agents for NMR, X-ray or radio diagnostics
JP3683584B2 (en) Dendritic polymer metal complexes, diagnostic agents containing the same, and methods for producing these complexes and diagnostic agents
EP3551614B1 (en) Dimeric contrast agents
CN111499633B (en) Chelate compound
US5010191A (en) Imaging agents for in vivo magnetic resonance and scintigraphic imaging
NO177783B (en) Heterocyclic polyamines
IE902964A1 (en) Use of amide complex compounds
US5399340A (en) Use of amide complex compounds
KR100376950B1 (en) Macrocyclic Chelants, Their Chelates and Uses Thereof in the Diagnostic Field
EP1045838B1 (en) 1,4,7,10-tetraazacyclododecane-1,4-diacetic acid
WO2004082721A1 (en) Complexes of gd +3 gadolinium ions with derivatives of n-2- (2- (phenylamino) -2- oxoethyl) -n- (carboxymethyl) - glycine and method for obtaining these complexes
EP0730586A1 (en) 1,4,7,10-tetraazacyclododecane derivatives, their use, pharmaceuticals containing them and process for their production
EP4206202A1 (en) Novel bispidine-based metal chelating ligands displaying good relaxivity
US6746662B1 (en) pH sensitive MRI contrast agents
JP3404787B2 (en) Novel diethylenetriaminepentaacetic acid derivative, complex compound of the derivative with a metal atom, and diagnostic agent containing the complex compound
EP3386953B1 (en) Contrast agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase